Auro-Repaglinide 1 mg (Repaglinide TABLET) 1 MG

AURO-REPAGLINIDE 1 MG tablets are an oral medication used to manage blood sugar levels in adults with type 2 diabetes. This prescription drug helps control glucose by stimulating insulin release from the pancreas.

Strength

1 MG

Pack Size

30/100/500/1000

Manufacturer / TM Owner

AURO PHARMA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Repaglinide is primarily used to improve glycemic control in adults with type 2 diabetes. It works by increasing insulin production in response to meals, helping to lower blood sugar levels. This medication is often prescribed as part of a broader diabetes management plan, which may include diet and exercise.

Side Effects

Common effects of repaglinide may include mild hypoglycemia, particularly if meals are skipped or delayed. Some users may experience gastrointestinal discomfort, such as nausea or diarrhea. It is important to monitor blood sugar levels regularly while using this medication.

Precautions & Warnings

Repaglinide should be taken as directed by a healthcare provider. It is important to follow the prescribed dosage and timing, especially in relation to meals. This medication may not be suitable for individuals with certain medical conditions, such as severe liver or kidney disease.

Avoid Interactions

Repaglinide may interact with other medications, including those that affect blood sugar levels or are metabolized by the liver. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be moderated while using repaglinide.

Frequently Asked Questions

Repaglinide is used to manage blood sugar levels in adults with type 2 diabetes by stimulating insulin release from the pancreas.

Repaglinide should be taken orally, typically before meals, as directed by a healthcare provider.

Common side effects may include hypoglycemia, nausea, and diarrhea. Regular blood sugar monitoring is recommended.

Repaglinide may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Repaglinide may not be suitable for individuals with severe liver or kidney disease. Always consult a healthcare provider before starting this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.